StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Up 10.7 %

Shares of Cara Therapeutics stock opened at $5.70 on Friday. Cara Therapeutics has a 12-month low of $2.71 and a 12-month high of $11.52. The firm has a market capitalization of $26.07 million, a price-to-earnings ratio of -0.27 and a beta of 0.50. The firm’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $4.18.

Institutional Trading of Cara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of Cara Therapeutics in the third quarter worth $29,000. FMR LLC increased its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares during the period. Curi RMB Capital LLC acquired a new stake in shares of Cara Therapeutics in the fourth quarter worth $277,000. Shay Capital LLC acquired a new stake in shares of Cara Therapeutics in the fourth quarter worth $524,000. Finally, Rockefeller Capital Management L.P. acquired a new stake in shares of Cara Therapeutics in the fourth quarter worth $953,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.